These findings suggest that increasing endogenous Cathepsin B activity could potentially reduce Aβ levels, particularly Aβ1-42, and protect against Alzheimer’s disease-related deficits (Sun et al., 2008). The gene discussed is CTSB; the disease is Alzheimer disease.